Record overview
Status and phase
Status: UNKNOWN
Phase: PHASE2
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition: Breast Cancer
NCT05806671
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Unknown Status Signal
Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.